EtR Framework:
Pfizer-BioNTech COVID-19 vaccine

Sara Oliver MD, MSPH
ACIP Meeting
December 12, 2020
Evidence to Recommendations Framework
Evidence to Recommendations (EtR) Framework

- Structure to describe information considered in moving from *evidence* to ACIP vaccine *recommendations*

- Provide *transparency* around the impact of additional factors on deliberations when considering a recommendation
Evidence to Recommendations (EtR) Framework

Policy Question

- Should vaccination with the Pfizer-BioNTech COVID-19 vaccine (2-doses, IM) be recommended for persons 16 years of age and older under an Emergency Use Authorization?
## Evidence to Recommendations (EtR) Framework: PICO Question

<table>
<thead>
<tr>
<th><strong>Population</strong></th>
<th>Persons aged ≥16 years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td>Pfizer-BioNTech COVID-19 vaccine (BNT162b2) 30µg, 2 doses IM, 21 days apart</td>
</tr>
<tr>
<td><strong>Comparison</strong></td>
<td>No vaccine</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Symptomatic laboratory-confirmed COVID-19 Hospitalization due to COVID-19 All-cause death SARS-CoV-2 seroconversion to a non-spike protein Asymptomatic SARS-CoV-2 infection Serious Adverse Events Reactogenicity grade ≥3</td>
</tr>
</tbody>
</table>
## Evidence to Recommendations (EtR) Framework

<table>
<thead>
<tr>
<th>EtR Domain</th>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health Problem</td>
<td>• Is the problem of public health importance?</td>
</tr>
<tr>
<td>Benefits and Harms</td>
<td>• How substantial are the desirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• How substantial are the undesirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• Do the desirable effects outweigh the undesirable effects?</td>
</tr>
<tr>
<td>Values</td>
<td>• Does the target population feel the desirable effects are large relative to the undesirable effects?</td>
</tr>
<tr>
<td></td>
<td>• Is there important variability in how patients value the outcomes?</td>
</tr>
<tr>
<td>Acceptability</td>
<td>• Is the intervention acceptable to key stakeholders?</td>
</tr>
<tr>
<td>Feasibility</td>
<td>• Is the intervention feasible to implement?</td>
</tr>
<tr>
<td>Resource Use</td>
<td>• Is the intervention a reasonable and efficient allocation of resources?</td>
</tr>
<tr>
<td>Equity</td>
<td>• What would be the impact of the intervention on health equity?</td>
</tr>
</tbody>
</table>
# Evidence to Recommendations (EtR) Framework

<table>
<thead>
<tr>
<th>EtR Domain</th>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health Problem</td>
<td>• Is the problem of public health importance?</td>
</tr>
<tr>
<td>Benefits and Harms</td>
<td>• How substantial are the desirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• How substantial are the undesirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• Do the desirable effects outweigh the undesirable effects?</td>
</tr>
<tr>
<td>Values</td>
<td>• Does the target population feel the desirable effects are large relative to the undesirable effects?</td>
</tr>
<tr>
<td></td>
<td>• Is there important variability in how patients value the outcomes?</td>
</tr>
<tr>
<td>Acceptability</td>
<td>• Is the intervention acceptable to key stakeholders?</td>
</tr>
<tr>
<td>Feasibility</td>
<td>• Is the intervention feasible to implement?</td>
</tr>
<tr>
<td>Resource Use</td>
<td>• Is the intervention a reasonable and efficient allocation of resources?</td>
</tr>
<tr>
<td>Equity</td>
<td>• What would be the impact of the intervention on health equity?</td>
</tr>
</tbody>
</table>

“The vaccine” or “The intervention” = Pfizer-BioNTech COVID-19 vaccine  
“The problem” = COVID-19 disease
EtR Domain: Public Health Problem
Public Health Problem

Is COVID-19 disease of public health importance?

- Are the consequences of COVID-19 serious?
- Is COVID-19 urgent?
- Are a large number of people affected by COVID-19?
- Are there populations disproportionately affected by COVID-19?

○ No  ○ Probably no  ○ Probably yes  ○ Yes  ○ Varies  ○ Don't know
Public Health Problem:
Review of the available evidence

January 21 – December 10

TOTAL CASES

15,474,800

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases
Hospitalization

- Cumulative hospitalization rate between March 1 and December 5, 2020 was **278.7** per 100,000 population
- Among those hospitalized, **32%** required care in an intensive care unit and **15%** died

Mortality

- As of December 10, 2020, there were **291,522** COVID-19-associated deaths reported in the United States
- Estimates of the SARS-CoV-2 infection fatality ratio range from 0.5% to 1.4%

https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html


Public Health Problem:
Work Group Interpretation

Is COVID-19 disease of public health importance?

- No
- Probably no
- Probably yes
- Yes
- Varies
- Don't know
EtR Domain: Benefits and Harms
Benefits and Harms

How substantial are the desirable anticipated effects?

- How substantial is the anticipated effect for each main outcome for which there is a desirable effect?

○ Minimal  ○ Small  ○ Moderate  ○ Large  ○ Varies  ○ Don't know
Benefits and Harms

How substantial are the undesirable anticipated effects?

- How substantial is the anticipated effect for each main outcome for which there is an undesirable effect?

○ Minimal  ○ Small  ○ Moderate  ○ Large  ○ Varies  ○ Don't know
Benefits and Harms

Do the desirable effects outweigh the undesirable effects?

- What is the balance between the desirable effects relative to the undesirable effects?

- Favors intervention (Pfizer-BioNTech COVID-19 vaccine)
- Favors comparison (no vaccine)
- Favors both
- Favors neither
- Unclear
Benefits and Harms: Summary of the Available Evidence: Benefits

- The clinical trial for the Pfizer-BioNTech COVID-19 vaccine demonstrated very high efficacy of the 2-dose regimen against symptomatic, laboratory-confirmed COVID-19. The overall efficacy was 95% (95% CI: 90.3%, 97.6%).  
  
  High certainty of evidence

- For hospitalization due to COVID-19, 5 events occurred, all in the placebo group. Vaccine effectiveness against hospitalization was 100% (95% CI: -9.9%, 100%).  
  
  Low certainty of evidence

- Deaths were uncommon, 2 in the vaccine group and 4 in the placebo group.  
  
  Very low certainty of evidence
Benefits and Harms:
Summary of the Available Evidence: Harms

- Serious adverse events were reported in a similar proportion among recipients of vaccine and placebo (0.6% vs 0.5%).
  
  *Moderate certainty of evidence*

- Severe reactions were more common in vaccinated; any grade $\geq 3$ reaction was reported by 8.8% of vaccinated vs. 2.1% of placebo group.
  
  *High certainty of evidence*
## Summary of GRADE

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Importance</th>
<th>Design (# of studies)</th>
<th>Findings</th>
<th>Evidence type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benefits</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomatic lab-confirmed COVID-19</td>
<td>Critical</td>
<td>RCT (1)</td>
<td>Pfizer-BioNTech COVID-19 vaccine is effective in preventing symptomatic COVID-19</td>
<td>1</td>
</tr>
<tr>
<td>Hospitalization due to COVID-19</td>
<td>Critical</td>
<td>RCT (1)</td>
<td>Pfizer-BioNTech COVID-19 vaccine may prevent COVID-19-resulting in hospitalization, but the uncertainty is high because this is a rare outcome</td>
<td>3</td>
</tr>
<tr>
<td>All-cause Death</td>
<td>Important</td>
<td>RCT (1)</td>
<td>Pfizer-BioNTech COVID-19 vaccine may prevent death, but the uncertainty is high because this is a rare outcome</td>
<td>4</td>
</tr>
<tr>
<td>SARS-CoV-2 seroconversion</td>
<td>Important</td>
<td>No studies</td>
<td>Data not yet available from any studies</td>
<td>ND</td>
</tr>
<tr>
<td>Asymptomatic SARS-CoV-2 infection</td>
<td>Important</td>
<td>No studies</td>
<td>Data not available from any studies</td>
<td>ND</td>
</tr>
<tr>
<td><strong>Harms</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Critical</td>
<td>RCT (2)</td>
<td>SAEs were balanced between vaccine and placebo arms. Two SAEs were judged to be related to vaccination.</td>
<td>2</td>
</tr>
<tr>
<td>Reactogenicity</td>
<td>Important</td>
<td>RCT (2)</td>
<td>Severe reactions were more common in vaccinated; any grade ≥3 reaction was reported by 8.8% of vaccinated vs. 2.1% of placebo group</td>
<td>1</td>
</tr>
</tbody>
</table>

Evidence type: 1=high; 2=moderate; 3=low; 4=very low; ND, no data.
How substantial are the desirable anticipated effects?

- How substantial is the anticipated effect for each main outcome for which there is a desirable effect?

○ Minimal  ○ Small  ○ Moderate  ○ Large  ○ Varies  ○ Don't know
Benefits and Harms

How substantial are the undesirable anticipated effects?

- How substantial is the anticipated effect for each main outcome for which there is an undesirable effect?

○ Minimal  ○ Small  ○ Moderate  ○ Large  ○ Varies  ○ Don't know
Benefits and Harms

Do the desirable effects outweigh the undesirable effects?
- What is the balance between the desirable effects relative to the undesirable effects?

- Favors intervention (Pfizer-BioNTech COVID-19 vaccine)
- Favors comparison (no vaccine)
- Favors both
- Favors neither
- Unclear
EtR Domain: Values
Values

Criteria 1:
Does the target population feel that the desirable effects are large relative to undesirable effects?

- How does the target population view the balance of desirable versus undesirable effects?
- Would patients feel that the benefits outweigh the harms and burden?
- Does the population appreciate and value Pfizer-BioNTech COVID-19 vaccine?

○ No  ○ Probably no  ○ Probably yes  ○ Yes  ○ Varies  ○ Don't know
Values

Criteria 2:
Is there important uncertainty about, or variability in, how much people value the main outcomes?

- How much do individuals value each outcomes in relation to the other outcomes?
- Is there evidence to support those value judgments?
- Is there evidence that the variability is large enough to lead to different decisions?

- Important uncertainty or variability
- Probably important uncertainty or variability
- Probably not important uncertainty or variability
- No important uncertainty or variability
- No known undesirable outcomes
Values:

Review of the available evidence

- Review of scientific literature
  - Databases: Medline, Embase, Psycinfo, Global Health Ovid, CINAHL, ProQuest Coronavirus Research, Scopus, WHO COVID-19
  - Search terms: SARS-CoV-2/COVID-19 string; vaccine string; intent, confidence, hesitancy, attitude, belief, accept, choice, decision, refusal
  - Last search date: December 10, 2020

- Inclusion criteria
  - Data collection in 2020 related to COVID-19 vaccine beliefs, attitudes, and intentions

- Review of scientific articles: 272 results, 14 papers included

- Review of news media and reports (Google): 19 sources included

- Preliminary findings from CDC vaccine intent survey and focus group discussions
Values:

Summary of the available evidence

- Overall acceptability of a COVID-19 vaccine was moderate\(^1\)
  - Proportion intending to receive vaccine ranged across surveys: 42-86%
  - Attitudes towards Pfizer-BioNTech vaccine with news reports of 90% efficacy: 71% believed effective, 68% safe
  - November survey: 70% likely if proven safe and effective by public health officials

- Vaccination intentions varied by time, population, and vaccine characteristics\(^1\)
  - Acceptance lowest among Black respondents, highest among Asian respondents
  - Acceptance greater with higher socioeconomic status
  - Acceptance greater with history of influenza vaccination and higher COVID-19 risk perception
  - Acceptance greater with higher vaccine efficacy and healthcare provider recommendation

COVID-19 Vaccination Intentions Varied by Survey Month

<table>
<thead>
<tr>
<th>Reference</th>
<th>Date</th>
<th>N</th>
<th>% Intent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Romer</td>
<td>Mar</td>
<td>1,050</td>
<td>82%</td>
</tr>
<tr>
<td>Fisher</td>
<td>Apr</td>
<td>991</td>
<td>58%</td>
</tr>
<tr>
<td>Earnshaw</td>
<td>Apr</td>
<td>845</td>
<td>86%</td>
</tr>
<tr>
<td>Southwell</td>
<td>Apr</td>
<td>2,279</td>
<td>75%</td>
</tr>
<tr>
<td>Roozenbeek</td>
<td>Apr</td>
<td>700</td>
<td>75%</td>
</tr>
<tr>
<td>Hogan</td>
<td>Apr</td>
<td>101</td>
<td>74%</td>
</tr>
<tr>
<td>Malik</td>
<td>May</td>
<td>672</td>
<td>67%</td>
</tr>
<tr>
<td>Taylor</td>
<td>May</td>
<td>1,772</td>
<td>75%</td>
</tr>
<tr>
<td>Reiter</td>
<td>May</td>
<td>2,006</td>
<td>69%</td>
</tr>
<tr>
<td>APNORC</td>
<td>May</td>
<td>1,056</td>
<td>49%</td>
</tr>
<tr>
<td>ICF</td>
<td>May</td>
<td>1,000</td>
<td>63%</td>
</tr>
<tr>
<td>Pew</td>
<td>May</td>
<td>10,957</td>
<td>72%</td>
</tr>
<tr>
<td>CUNY</td>
<td>May</td>
<td>1,999</td>
<td>74%</td>
</tr>
<tr>
<td>Head</td>
<td>May</td>
<td>3,159</td>
<td>66%</td>
</tr>
<tr>
<td>Lazarus</td>
<td>Jun</td>
<td>773</td>
<td>75%</td>
</tr>
<tr>
<td>ICF</td>
<td>Jun</td>
<td>1,000</td>
<td>63%</td>
</tr>
<tr>
<td>Perlis</td>
<td>Jul</td>
<td>19,027</td>
<td>66%</td>
</tr>
<tr>
<td>Romer</td>
<td>Jul</td>
<td>840</td>
<td>72%</td>
</tr>
<tr>
<td>Pogues</td>
<td>Aug</td>
<td>316</td>
<td>69%</td>
</tr>
<tr>
<td>KFF</td>
<td>Sep</td>
<td>1,199</td>
<td>42%</td>
</tr>
<tr>
<td>Pew</td>
<td>Sep</td>
<td>10,093</td>
<td>51%</td>
</tr>
<tr>
<td>Harris</td>
<td>Sep</td>
<td>1,971</td>
<td>54%</td>
</tr>
<tr>
<td>Gallup</td>
<td>Oct</td>
<td>2,985</td>
<td>58%</td>
</tr>
<tr>
<td>IPSOS</td>
<td>Oct</td>
<td>3,541</td>
<td>62%</td>
</tr>
<tr>
<td>USC</td>
<td>Nov</td>
<td>2,703</td>
<td>63%</td>
</tr>
<tr>
<td>Harris</td>
<td>Nov</td>
<td>1,963</td>
<td>60%</td>
</tr>
<tr>
<td>Pew</td>
<td>Nov</td>
<td>12,948</td>
<td>60%</td>
</tr>
<tr>
<td>Axios-Ipsos</td>
<td>Nov</td>
<td>1,002</td>
<td>51%</td>
</tr>
<tr>
<td>Axios-Ipsos</td>
<td>Dec</td>
<td>1,101</td>
<td>53%</td>
</tr>
<tr>
<td>APNORC</td>
<td>Dec</td>
<td>1,117</td>
<td>47%</td>
</tr>
<tr>
<td>Quinnipiac</td>
<td>Dec</td>
<td>978</td>
<td>61%</td>
</tr>
</tbody>
</table>

*Positive vaccine intentions includes persons reporting definitely, probably, or somewhat likely to get vaccinated.
COVID-19 Vaccination Intentions Varied by Race/ethnicity

*Positive vaccine intentions includes persons reporting definitely, probably, or somewhat likely to get vaccinated.
Values:
Summary of the available evidence

- Many adults reported intentions to receive COVID-19 vaccine
  - Common desirable effects included protecting self, family, community from SARS-CoV-2 infection and severe illness and return to normalcy
  - Common concerns included vaccine side effects, uncertainty of vaccine efficacy, and speed of vaccine approval process

- Vaccination intentions varied substantially by race or ethnicity and socioeconomic status of respondents

- Limitations:
  - Most surveys conducted prior to availability of specific information on Pfizer-BioNTech COVID-19 vaccine
  - Convenience samples may not be representative
### Values: Work Group Interpretation

#### Criteria 1:
Does the target population feel that the desirable effects are large relative to undesirable effects?

- No
- Probably no
- ** Probably yes
- Yes
- Varies
- Don't know
### Values: Work Group Interpretation

**Criteria 2:**

Is there important uncertainty about, or variability in, how much people value the main outcomes?

<table>
<thead>
<tr>
<th>Important uncertainty or variability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probably important uncertainty or variability</td>
</tr>
<tr>
<td>Probably not important uncertainty or variability</td>
</tr>
<tr>
<td>No important uncertainty or variability</td>
</tr>
<tr>
<td>No known undesirable outcomes</td>
</tr>
</tbody>
</table>
EtR Domain: Acceptability
Acceptability

Is Pfizer/BioNTech COVID-19 vaccine acceptable to key stakeholders?

- Are there key stakeholders that would not accept the distribution of benefits and harms?
- Are there key stakeholders that would not accept the undesirable effects in the short term for the desirable effects (benefits) in the future?

○ No  ○ Probably no  ○ Probably yes  ○ Yes  ○ Varies  ○ Don't know
Acceptability:
Review of the available evidence

- Review of scientific literature
- Preliminary findings from CDC evaluations of COVID-19 vaccine attitudes
  - Survey with State Health Officers (n=34)
  - Focus group discussions with nurses (7 focus groups)
  - National online survey: sub-group analysis for healthcare providers (n=216)
- Review of news media, professional society and workers’ unions websites
  - AAFP, AFT, AFSCME, AGS, ANA, AMA, IDSA, SEIU
  - American Nurses Foundation (ANF) survey (n=12,939)
- Consideration of programmatic, financial, and ethical aspects
  - State/jurisdiction and partner planning for vaccine implementation
  - Anticipated out-of-pocket costs
Acceptability:
Summary of the available evidence

- No published provider knowledge, attitudes, and practices surveys
- CDC evaluations
  - State health officers, Oct: concerns with rollout included vaccine hesitancy (53%), vaccine safety (32%), and communications (26%)\(^1\)
  - Focus groups with nurses (n=7 groups), Jun-Aug: most supported prioritizing nurses, some reluctant to get vaccinated, and many do not want to get it right away\(^2\)
  - Vaccine intent survey, Sep-Oct: 63% healthcare providers would get COVID-19 vaccine\(^3\)
- ANF nurses survey, Oct: moderate acceptability of COVID-19 vaccine\(^4\)
  - 63% somewhat or very confident vaccine will be safe and effective
  - 57% comfortable discussing COVID-19 vaccines with patients

Acceptability: Summary of the available evidence

- All jurisdictions have submitted COVID-19 vaccine implementation plans
- Large and small pharmacy chains have committed to participate in COVID-19 vaccination program
- In a CDC survey of 34 state health officers in October, common concerns about vaccine administration included vaccine hesitancy, vaccine safety, and communications
Acceptability:
Work Group Interpretation

Is the Pfizer/BioNTech COVID-19 vaccine acceptable to key stakeholders?

○ No  ○ Probably no  ○ Probably yes  ○ Yes  ○ Varies  ○ Don't know
EtR Domain: Feasibility
Feasibility

Is the Pfizer/BioNTech COVID-19 vaccine feasible to implement?

- Is the Pfizer-BioNTech COVID-19 vaccine program sustainable?
- Are there barriers that are likely to limit the feasibility of implementing the Pfizer-BioNTech COVID-19 vaccine or require consideration when implementing it?
- Is access to Pfizer-BioNTech COVID-19 vaccine an important concern?

○ No ○ Probably no ○ Probably yes ○ Yes ○ Varies ○ Don't know
Feasibility:
Summary of the available evidence

- Barriers to implementation may include:
  1) Financial barriers
  2) Complexity of recommendations
  3) Vaccine storage and handling requirements
Feasibility:
Summary of the available evidence

1) Financial barriers

- All COVID-19 vaccines will be provided to U.S. population free of charge
- Health systems or health departments could incur costs for vaccine implementation, clinics
Feasibility:
Summary of the available evidence

2) Complexity of recommendations
Feasibility:
Summary of the available evidence

3) Vaccine storage and handling requirements

- Access to healthcare could be limited in rural or other hard-to-reach areas
- Ultra-cold storage requirements (-80°C to -60°C) will limit the range of healthcare providers stocking vaccine
- Minimum size of orders (currently 975 doses)
- Requirements for two-dose series
Feasibility:
Summary of the available evidence

- **Innovative** solutions to overcome barriers:
  - Expanded funding opportunities
  - Pharmacy partnerships
  - Technology, including second dose reminders
  - Unique packing containers to maintain ultra-cold temperatures without freezer
  - Detailed state micro-planning
Is Pfizer/BioNTech COVID-19 vaccine feasible to implement?

- No
- Probably no
- Probably yes
- Yes
- Varies
- Don't know
EtR Domain: Resource Use
Resource Use

Is Pfizer-BioNTech COVID-19 vaccine a reasonable and efficient allocation of resources?

- What is the cost-effectiveness of the Pfizer-BioNTech COVID-19 vaccine?
- How does the cost-effectiveness of the Pfizer-BioNTech COVID-19 vaccine change in response to changes in context, assumptions, etc?

○ No ○ Probably no ○ Probably yes ○ Yes ○ Varies ○ Don't know
Resource Use:
Review of the available evidence

- Work Group reviewed estimates of economic costs related to COVID-19 vaccinations, disease outcomes and disease mitigation activities
Resource Use:
Summary of the available evidence

Costs associated with COVID-19 disease

- If 20% of the U.S. population is infected with COVID-19, the direct medical costs could be $163 billion\(^1\)

- Health-related costs (including premature deaths, long-term health impairment and mental health impairment) have been estimated at $8.5 trillion\(^2\)

---

Resource Use:
Summary of the available evidence

Costs associated with COVID-19 disease

- If 20% of the U.S. population is infected with COVID-19, the direct medical costs could be $163 billion

- Health-related costs (including premature deaths, long-term health impairment and mental health impairment) have been estimated at $8.5 trillion

Costs associated with COVID-19 vaccines

- U.S. Government has committed $10 billion to Operation Warp Speed for the provision of vaccines

- Vaccine doses purchased with U.S. taxpayer dollars will be given to the American people at no cost


Resource Use:
Work Group Interpretation

- No published cost-effectiveness analyses currently available

- Precise cost-effectiveness analysis and economic impact of vaccination depend on number of factors that are currently unknown:
  - Duration of vaccine protection
  - Vaccination coverage levels
  - Implementation costs associated with large vaccination program

- The Work Group concluded that cost-effectiveness may not be a primary driver for decision-making during a pandemic and for vaccine used under EUA
  - Will need to be reassessed for future recommendations
Resource Use:

Work Group Interpretation

Is Pfizer/BioNTech COVID-19 vaccine a reasonable and efficient allocation of resources?

- No
- Probably no
- Probably yes
- Yes
- Varies
- Don't know
EtR Domain: Equity
Equity

What would be the impact of the Pfizer-BioNTech COVID-19 vaccine on health equity?

- Are there groups or settings that might be disadvantaged in relation to COVID-19 disease burden or receipt of the Pfizer-BioNTech COVID-19 vaccine?
- Are there considerations that should be made when implementing the Pfizer-BioNTech COVID-19 vaccine program to ensure that inequities are reduced whenever possible, and that they are not increased?

- Reduced
- Probably reduced
- Probably no impact
- Probably increased
- Increased
- Varies
- Don't know
Equity:
Review of the available evidence

- Identification of groups that might be disadvantaged in relation to COVID-19 disease burden or receipt of the Pfizer-BioNTech COVID-19 vaccine
  - PROGRESS-Plus Framework:¹ Place of residence, race or ethnicity, occupation, gender or sex, religion, education, socioeconomic status, social capital, disability, other

- Review of the scientific and gray literature

- Review of CDC COVID-19 response data and resources
  - CDC COVID Data Tracker & COVID-19-Associated Hospitalization Surveillance Network (COVID-NET)
  - National Center for Health Statistics
  - COVID-19 Disproportionately Affected Populations Team critical populations review

Equity: Groups who might be unfairly disadvantaged in relation to COVID-19 disease burden or receipt of the Pfizer-BioNTech COVID-19 vaccine

- Racial and ethnic minority populations
- People living in poverty or with high social vulnerability
- Essential workers
  - Some racial/ethnic minority populations disproportionately represented in subsets of essential workers, e.g., public transit, building cleaning services, construction, food and agriculture\(^1\)-\(^3\)
  - Almost one quarter live in low-income families\(^1\)
- Residents in congregate settings, such as long-term care facilities, prisons, homeless shelters, and group homes for people with intellectual/developmental disabilities
- People with substance abuse disorders
- Sexual and gender minorities
  - Face social or structural inequities that can lead to health disparities

Equity: Characteristics of the Pfizer-BioNTech COVID-19 vaccine that could impact health equity

- Cold chain storage, handling, and administration requirements
  - Limit the number and types of facilities that can receive and use the vaccine
  - Impact equitable distribution if the vaccine is primarily accessed at large health centers or central distribution sites rather than local community settings

- Need for 2-dose series
  - Follow-up may be challenging for some disadvantaged groups, e.g., those who are homeless, live in rural locations, have no/limited access to healthcare
**Equity:** Opportunities to increase equitable access to the Pfizer-BioNTech COVID-19 vaccine

- Federal Pharmacy Partnership for COVID-19 Vaccination in Long-term Care Facilities Program
  - Facilitates access to Pfizer-BioNTech COVID-19 vaccine in LTCF residents and staff
  - Provides end-to-end management of the COVID-19 vaccination process, including cold chain management and on-site vaccinations

- Healthcare facilities that can administer/provide access to the vaccine
  - Offers the potential to increase equitable distribution of the Pfizer-BioNTech COVID-19 vaccine in HCP
Equity:
Additional considerations

- Although COVID-19 vaccines will be provided at no cost, personal investments in time and travel to obtain vaccine may be a barrier for some groups.

- Equity and vaccination program implementation are closely linked
  - The Work Group emphasized that federal, state and local jurisdictions require adequate resources to get COVID-19 vaccines to the most affected communities and ensure equitable access.

- Successful implementation of the COVID-19 vaccination program and confidence in COVID-19 vaccines are pivotal to reducing existing health inequities related to COVID-19.
Equity: Additional information questions

- Are there considerations that should be made when implementing the Pfizer-BioNTech COVID-19 vaccine program to ensure inequities are reduced whenever possible, and that they are not increased?
  - Identify groups disproportionately affected by COVID-19 or who face health inequities
  - Undertake focused outreach and education
  - Identify and address barriers to vaccination
  - Conduct active follow-up of disadvantaged groups to ensure completion of a 2-dose series
**Equity: Summary**

- Successful implementation of the COVID-19 vaccination program and confidence in COVID-19 vaccines are **pivotal** to reducing health inequities.

  “…increasing the availability of an effective intervention within a country or region is not necessarily enough to reduce inequities. The intervention has to be accessible, acceptable, effective in, and used by the most disadvantaged groups within that population to be truly effective at reducing inequities in health”.¹

Equity:

Work Group Interpretation

What would be the impact of Pfizer-BioNTech COVID-19 vaccine on health equity?

- Reduced
- Probably reduced
- Probably no impact
- Probably increased
- Increased
- Varies
- Don't know
Summary
<table>
<thead>
<tr>
<th>EtR Domain</th>
<th>Question</th>
<th>Work Group Judgments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public Health Problem</strong></td>
<td>Is COVID-19 disease of public health importance?</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Benefits and Harms</strong></td>
<td>How substantial are the desirable anticipated effects?</td>
<td>Large</td>
</tr>
<tr>
<td></td>
<td>How substantial are the undesirable anticipated effects?</td>
<td>Small</td>
</tr>
<tr>
<td></td>
<td>Do the desirable effects outweigh the undesirable effects?</td>
<td>Favors Pfizer-BioNTech COVID-19 vaccine</td>
</tr>
</tbody>
</table>
|                       | What is the overall certainty of the evidence for the critical outcomes?| 1 (high) for prevention of symptomatic COVID-19  
|                       |                                                                         | 3 (low) for hospitalization        |
|                       |                                                                         | 2 (moderate) for safety            |
| **Values**            | Does the target population feel the desirable effects are large relative to the undesirable effects? | Probably Yes                       |
|                       | Is there important variability in how patients value the outcomes?      | Probably important uncertainty     |
| **Acceptability**     | Is the Pfizer-BioNTech COVID-19 vaccine acceptable to key stakeholders? | Probably Yes                       |
| **Feasibility**       | Is the Pfizer-BioNTech COVID-19 vaccine feasible to implement?           | Probably Yes                       |
| **Resource Use**      | Is Pfizer-BioNTech COVID-19 vaccine a reasonable and efficient allocation of resources? | Yes                                |
| **Equity**            | What would be the impact of the intervention on health equity?           | Probably reduced                   |
### Evidence to Recommendations Framework

#### Summary: Work Group Interpretations

<table>
<thead>
<tr>
<th>Balance of consequences</th>
<th>Undesirable consequences clearly outweigh desirable consequences in most settings</th>
<th>Undesirable consequences probably outweigh desirable consequences in most settings</th>
<th>The balance between desirable and undesirable consequences is closely balanced or uncertain</th>
<th>Desirable consequences probably outweigh undesirable consequences in most settings</th>
<th>Desirable consequences clearly outweigh undesirable consequences in most settings</th>
<th>There is insufficient evidence to determine the balance of consequences</th>
</tr>
</thead>
</table>

Desirable consequences probably outweigh undesirable consequences in most settings

Desirable consequences clearly outweigh undesirable consequences in most settings

Undesirable consequences probably outweigh desirable consequences in most settings

Undesirable consequences clearly outweigh desirable consequences in most settings

There is insufficient evidence to determine the balance of consequences
Evidence to Recommendations Framework
Summary: Work Group Interpretations

<table>
<thead>
<tr>
<th>Balance of consequences</th>
<th>Undesirable consequences clearly outweigh desirable consequences in most settings</th>
<th>Undesirable consequences probably outweigh desirable consequences in most settings</th>
<th>The balance between desirable and undesirable consequences is closely balanced or uncertain</th>
<th>Desirable consequences probably outweigh undesirable consequences in most settings</th>
<th>Desirable consequences clearly outweigh undesirable consequences in most settings</th>
<th>There is insufficient evidence to determine the balance of consequences</th>
</tr>
</thead>
</table>
## Evidence to Recommendations Framework

### Summary: Work Group Interpretations

<table>
<thead>
<tr>
<th>Type of recommendation</th>
<th>We do not recommend the intervention</th>
<th>We recommend the intervention for individuals based on shared clinical decision-making</th>
<th>We recommend the intervention</th>
</tr>
</thead>
</table>


| Type of recommendation | We do not recommend the intervention | We recommend the intervention for individuals based on shared clinical decision-making | We recommend the intervention |

Evidence to Recommendations Framework
Summary: Work Group Interpretations
Thank you

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Public Health Problem:
Summary of the available evidence

- **Risk factors for severe disease**
  - Older adults and those with certain medical conditions are at increased risk for severe illness from COVID-19
  - Among persons hospitalized with COVID-19, **90%** had ≥1 underlying condition and **41%** were ≥65 years of age
    - Among persons who died with COVID-19, **76%** had ≥1 underlying medical condition and **80%** were ≥65 years of age
  - Approximately **25%** of COVID-19-associated deaths were among nursing home residents

https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html
State of pandemic in US: ~200,000 new cases/day, ~2,750 new deaths/day

High transmissibility of the virus,

Estimated low population-level immunity

Estimated 5% develop critical illness, of which case fatality is high (49%)\(^a\)

Lack of FDA-approved treatment or prophylactic

Unknown adverse events in general population, pregnant & breastfeeding women, frail elderly, etc.

Unknown benefit in preventing asymptomatic infection and transmission No data

Unknown duration of protection against symptomatic illness

---

Strategies to consider for overcoming barriers to vaccine acceptance:

- **Engage trusted sources** (e.g., social workers, faith leaders, community leaders, advocacy groups, facility administrators, union representatives)
- **Develop communication materials** that are ADA-compliant and culturally, linguistically, and literacy appropriate
- **Ensure providers have information** on vaccine recommendations to counsel patients
- **Educate throughout jurisdiction** about vaccination recommendations and where to refer patients for free COVID-19 vaccination
- **Educate non-clinical facility administrators**
Values:
Summary of the available evidence

- Common reasons for not intending to get vaccinated included¹:
  - Concern for vaccine side effects
  - Uncertainty of vaccine efficacy
  - Low risk perception of COVID-19 or severe disease
- Vaccine efficacy (90% or 70%) associated with preferred choice of hypothetical vaccine²
- Focus groups (49, n=239): most are open to vaccine, but many prefer not to be first³
- Many reported concerns that COVID-19 vaccine approval process was too fast¹
- Limitations
  - Most surveys conducted prior to availability of specific information on Pfizer-BioNTech COVID-19 vaccine
  - Convenience samples may not be representative